发明名称 Therapy for complications of diabetes
摘要 A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.
申请公布号 US8865650(B2) 申请公布日期 2014.10.21
申请号 US201314079464 申请日期 2013.11.13
申请人 AbbVie Deutschland GmbH & Co. KG 发明人 Roden Robert L.;Gorczynski Richard J.;Gerber Michael J.
分类号 A61K45/06;A61K31/549;A61K31/505;A61K31/4025 主分类号 A61K45/06
代理机构 Neal, Gerber & Eisenberg LLP 代理人 Neal, Gerber & Eisenberg LLP
主权项 1. A method for treating diabetic nephropathy in a human subject in need of such treatment, said method comprising: administering to the subject atrasentan or a salt thereof, and a dose of at least one angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker.
地址 Wiesbaden DE
您可能感兴趣的专利